Price range: $80.00 through $115.00
Semaglutide (GLP-1) + Cagrilintide (Amylin Analog)
Contents: Semaglutide 50% + Cagrilintide 50%
Form: Lyophilized Powder
Purity: ≥ 99% pure
Emerging Research Evidence:
Increases Weight Loss, Reduces Appetite, Increases Feelings of Fullness and Manages Blood Glucose Levels
Keep product in cool, dark place.
Sold for Research Use Only / Not FDA Regulated
GLP-1 + Amylin Analog (CagriSema) Overview
CagriSema is a co-formulated peptide blend of Cagrilintide (amylin analog) which is the suppression of hunger hormone; semaglutide is a GLP-1 receptor agonist. Together they’re being studied for chronic weight management and type 2 diabetes. In Phase 3 trials (REDEFINE), the combo produced ~22.7% average weight loss at 68 weeks in adults without diabetes and ~15.7% in adults with type 2 diabetes, with improvements in blood sugar and other cardiometabolic measures. Research is ongoing and the claimed benefits are still emerging.
CagriSema Structure:
Cagrilintide
CAS Number: 1415456-99-3
Molecular Formula: C₁₉₄H₃₁₂N₅₄O₅₉S₂
Molecular Weight (avg): ≈ 4409.0 g/mol
Monoisotopic Mass (exact): ≈ 4406.25 Da
Parent compound: analog of human amylin (amylin/calcitonin receptor agonist).
Synonyms:
Semaglutide
Synonyms/brands:
Research Areas:
Research-only note: GLP-1 CS is not FDA-approved for therapeutic use; published effects are primarily preclinical and exploratory.
| Size | 5mg, 10mg |
|---|
For Research Use Only — Not for Human or Veterinary Use. Not evaluated or approved by the FDA. Not intended to diagnose, treat, cure, or prevent any disease. All information on this website is provided strictly for laboratory research and educational purposes. Nothing herein constitutes medical, clinical, or legal advice, nor an endorsement of non-laboratory use. Any discussion of specific peptides or potential research findings is informational only and must not be interpreted as guidance for use in or on humans or animals.
